Navigation Links
Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA

RIDGEFIELD, Conn., Oct. 5 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted full (traditional) approval of Aptivus(R) (tipranavir) capsules. The FDA granted accelerated approval to APTIVUS in June 2005; accelerated approval is a regulatory process that expedites the approval of therapies for serious or life-threatening illnesses. The full approval of APTIVUS is based largely on 48-week analyses of the Phase 3 pivotal clinical studies known as the RESIST (Randomized Evaluation of Strategic Intervention in Multi-Drug ReSistant Patients with Tipranavir) trials. These trials comprise one of the largest study programs conducted in treatment-experienced HIV patients.

"Data show that APTIVUS/r may provide treatment-experienced HIV patients with an effective treatment option through nearly one year of therapy. Furthermore, longer-term safety data are now available for physician and patient consideration," said Dr. Daniel Kuritzkes, associate professor of medicine, Harvard Medical School; director of AIDS research, Brigham and Women's Hospital, Boston, MA.

APTIVUS, a protease inhibitor, co-administered with 200 mg of ritonavir (APTIVUS/r), is indicated for combination antiretroviral treatment of HIV-1 infected adult patients who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor.

This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/r of 48 weeks duration. Both studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

The following points should be considered when initiating therapy with APTIVUS/r:

-- The use of APTIVUS/r in treatment-nave patients is not recommended.

-- The use of other active agents with APTIVUS/r is associated with a

greater likelihood of treatment response.

-- Genotypic or phenotypic testing and/or treatment history should guide

the use of APTIVUS/r. The number of baseline primary protease

inhibitor mutations affects the virologic response to APTIVUS/r.

-- Use caution when prescribing APTIVUS/r to patients with elevated

transaminases, hepatitis B or C co-infection or patients with mild

hepatic impairment.

-- Liver function tests should be performed at initiation of therapy with

APTIVUS/r and monitored frequently throughout the duration of


-- The drug-drug interaction potential of APTIVUS/r when co-administered

with other drugs must be considered prior to and during APTIVUS/r use.

-- Use caution when prescribing APTIVUS/r in patients who may be at risk

for increased bleeding or who are receiving medications known to

increase the risk of bleeding.

-- The risk-benefit of APTIVUS/r has not been established in pediatric


There are no study results demonstrating the effect of APTIVUS/r on clinical progression of HIV-1.

APTIVUS/r does not cure HIV or help prevent passing HIV to others.


The RESIST clinical trial program consists of two ongoing Phase 3 pivotal trials, RESIST-1 and RESIST-2. Comprising one of the largest study programs conducted in treatment-experienced HIV patients, RESIST-1 includes 620 patients in the U.S., Canada and Australia, and RESIST-2 includes 863 patients in Europe and Latin America. The trial design and baseline patient characteristics are similar across studies. Patients enrolled in the RESIST studies were failing their current PI-based regimen, had received at least two previous PI-based regimens, had received prior treatment from at least three classes of antiretroviral agents and had documented PI resistance.

At the time of full approval, the studies examined treatment response, defined as a confirmed 1 log10 or greater decrease in the amount of HIV in the blood, or viral load, at 48 weeks versus a comparator group in which patients received one of several marketed ritonavir-boosted PIs. Investigators selected a comparator PI (CPI/r) that offered patients the best opportunity for treatment response based on resistance testing. The comparator PIs were lopinavir, indinavir, saquinavir and amprenavir. In addition, patients in both arms received an optimized background regimen of other antiretroviral drugs. Patients were treatment-experienced and the majority (85.1%) were at least possibly resistant to the comparator PI chosen.

Analysis of the primary endpoint at week 48 demonstrated that more than twice the percentage of patients (33.8%) treated with APTIVUS/r achieved a treatment response compared to those patients treated with a CPI/r (14.9%). The median change from baseline in HIV-1 viral load at the last measurement up to week 48 was -0.64 log10 copies/mL in APTIVUS/r patients versus -0.22 log10 copies/mL in CPI/r patients.

Secondary endpoints included reduction in viral load to less than 400 copies/mL or 50 copies/mL and increase in CD4+ cell count. Through 48 weeks of treatment, more than twice the percentage of patients in the APTIVUS/r arm achieved a viral load of less than 400 copies/mL (30.3%) compared to the CPI/r arm (13.6%). Regarding a viral load of less than 50 copies/mL, 22.7% of APTIVUS/r patients achieved this level compared to 10.2% of CPI/r patients. The median change from baseline in CD4+ cell count at the last measurement up to week 48 was +23 cells/mm3 in APTIVUS/r patients (n=740) versus +4 cells/mm3 in CPI/r patients (n=727).

According to HIV treatment guidelines, achieving and maintaining an undetectable viral load -- less than 50 copies/mL of blood -- is the goal of HIV therapy.(1)

The APTIVUS labeling includes boxed warnings for reports of:

-- Clinical hepatitis and hepatic decompensation including some

fatalities. Extra vigilance is warranted in patients with chronic

hepatitis B or hepatitis C co-infection, as these patients have an

increased risk of hepatotoxicity.

-- Both fatal and non-fatal intracranial hemorrhage (ICH).

The most commonly reported adverse events in patients taking APTIVUS/r are diarrhea, nausea, fever, vomiting, fatigue, headache and abdominal pain. The most common laboratory abnormalities are elevated liver enzymes (AST/ALT) and triglycerides.

"For more than a decade, Boehringer Ingelheim has been at the forefront of developing innovative therapies for HIV patients. The full approval of APTIVUS further demonstrates our commitment to HIV/AIDS," said Dr. Thor Voigt, Senior Vice President, Medicine and Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We have developed a robust clinical trial program around APTIVUS. In addition to RESIST, clinical trials for treating HIV are in progress in racially, ethnically and gender diverse patients and hepatitis co-infected patients. A trial comparing the efficacy and safety of APTIVUS/r versus darunavir/r, both as part of combination antiretroviral therapy, is also planned."

Important Safety Information for APTIVUS

-- APTIVUS/r has been associated with reports of clinical hepatitis and

hepatic decompensation, including some fatalities. Extra vigilance is

warranted in patients with chronic hepatitis B or hepatitis C co-

infection, as these patients have an increased risk of hepatotoxicity.

Patients with signs or symptoms of clinical hepatitis should

discontinue APTIVUS/r treatment and seek medical evaluation.

-- APTIVUS/r has been associated with reports of both fatal and non-fatal

intracranial hemorrhage (ICH).

-- All patients should be followed closely with clinical and laboratory

monitoring, especially those with chronic hepatitis B or C co-

infection, as these patients have an increased risk of hepatotoxicity.

Liver function tests should be performed prior to initiating therapy

with APTIVUS/r, and frequently throughout the duration of treatment.

-- Treatment-experienced patients with chronic hepatitis B or hepatitis C

co-infection or elevations in transaminases are at approximately 2-fold

risk for developing Grade 3 or 4 transaminase elevations or hepatic

decompensation. In the RESIST trials, Grade 3 and 4 increases in

hepatic transaminases were observed in 10.3% (10.9/100 PEY) of patients

receiving APTIVUS/r through week 48. In a study of treatment-nave

patients, 20.3% (21/100 PEY) experienced Grade 3 or 4 hepatic

transaminase elevations while receiving APTIVUS/r through week 48.

-- APTIVUS/r is contraindicated in patients with moderate or severe

(Child-Pugh Class B or C, respectively) hepatic impairment.

-- The drug-drug interaction potential of APTIVUS/r when co-administered

with multiple classes of drugs must be considered prior to and during

APTIVUS/r use.

-- APTIVUS/r is contraindicated with amiodarone, bepridil, flecainide,

propafenone, quinidine, rifampin, dihydroergotamine, ergonovine,

ergotamine, methylergonovine, cisapride, St. John's wort, lovastatin,

simvastatin, pimozide, midazolam and triazolam due to the potential for

serious and/or life-threatening events or loss of efficacy.

-- A drug interaction study in healthy subjects has shown that ritonavir

significantly increases plasma fluticasone propionate exposures.

Concomitant use of APTIVUS/r and fluticasone propionate may produce

systemic corticosteroid side effects, including Cushing's syndrome and

adrenal suppression. APTIVUS/r should not be taken with fluticasone

propionate, inhaled or intranasally administered, unless the potential

benefit to the patient outweighs the risk.

-- Caution should be used when prescribing sildenafil, tadalafil, and

vardenafil with APTIVUS/r because concentrations of these drugs may


-- Caution should be used when prescribing carbamazepine, phenobarbital

and/or phenytoin. APTIVUS may be less effective due to decreased

tipranavir plasma concentrations.

-- Caution should be used when prescribing valproic acid. Valproic acid

may be less effective due to decreased valproic acid plasma


-- Use caution when prescribing APTIVUS/r in patients who may be at risk

of increased bleeding from trauma, surgery or other medical conditions,

or who are receiving medications known to increase the risk of bleeding

such as antiplatelet agents and anticoagulants, or who are taking

supplemental high doses of vitamin E. In in vitro experiments,

tipranavir was observed to inhibit human platelet aggregation at levels

consistent with exposures observed in patients receiving APTIVUS/r. In

rats, co-administration with vitamin E increased the bleeding effects

of tipranavir.

-- Rash, including urticarial rash, maculopapular rash, and possible

photosensitivity, has been reported in patients receiving APTIVUS/r. In

some, rash was accompanied by joint pain or stiffness, throat

tightness, or generalized pruritus. In controlled clinical trials, rash

(all grades, all causality) was observed in 10% of females and in 8% of

males receiving APTIVUS/r through 48 weeks of treatment. The median

time to onset of rash was 53 days and the median duration of rash was

22 days. The discontinuation rate for rash in clinical trials was

0.5%. In an uncontrolled compassionate use program (n=3,920), cases of

rash, some of which were severe, accompanied by myalgia, fever,

erythema, desquamation, and mucosal erosions were reported.

Discontinue and initiate appropriate treatment if severe skin rash


-- APTIVUS should be used with caution in patients with a known

sulfonamide allergy.

-- New onset diabetes mellitus, exacerbation of pre-existing diabetes

mellitus, hyperglycemia and increased bleeding (in patients with

hemophilia) have been reported in patients taking protease inhibitors.

A causal relationship between protease inhibitors and these events has

not been established.

-- Immune reconstitution syndrome has been reported in patients treated

with combination antiretroviral therapy, including APTIVUS/r.

-- Redistribution and/or accumulation of body fat have been observed in

patients receiving antiretroviral therapy. A causal relationship has

not been established.

-- Treatment with APTIVUS/r has resulted in large increases in total

cholesterol and triglycerides, which should be monitored prior to and

during APTIVUS/r therapy.

-- Because the potential for HIV cross-resistance among protease

inhibitors has not been fully explored in APTIVUS/r-treated patients,

it is unknown what effect therapy with APTIVUS will have on the

activity of subsequently administered protease inhibitors.

-- APTIVUS must be co-administered with 200 mg of ritonavir to exert its

therapeutic effect. Failure to correctly co-administer APTIVUS with

ritonavir will result in reduced plasma levels of tipranavir that will

be insufficient to achieve the desired antiviral effect and will alter

some drug interactions.

-- Please refer to the complete ritonavir prescribing information for a

description of ritonavir contraindications and additional information

on precautionary measures.

-- In clinical trials, the most frequently reported adverse events

associated with APTIVUS/r were diarrhea, nausea, fever, vomiting,

fatigue, headache and abdominal pain.

Please see full Prescribing Information (PI), including boxed WARNINGS, for APTIVUS at The PI is in the new Physicians Labeling Rule (PLR) format required by the U.S. FDA.

Additional Information about APTIVUS

APTIVUS, a non-peptidic protease inhibitor, works by inhibiting protease, an enzyme needed to complete the HIV replication process. The approved dose of APTIVUS is 500 mg taken with 200 mg of ritonavir, twice daily.

APTIVUS is also approved in Argentina, Australia, Canada, Switzerland, Mexico, Iceland, Taiwan and the European Union.

Boehringer Ingelheim is actively conducting a clinical trial program to further evaluate APTIVUS for the treatment of HIV-1 infection. The program is comprised of ongoing and planned studies in more than 1,000 HIV-infected patients.

About Boehringer Ingelheim

Boehringer Ingelheim is committed to improving HIV therapy by providing physicians and patients with innovative antiretroviral agents.

For more information on Boehringer Ingelheim Pharmaceuticals, Inc., please visit

(1) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, October 10, 2006; Treatment for Adult HIV Infection. 2006 Recommendations of the International AIDS Society - - USA Panel. JAMA. 296(7): 837. August 16, 2006.

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
2. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
3. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Ardelyx, Inc. (NASDAQ: ... on gastrointestinal and cardio-renal diseases, today announced that ... tenapanor, will be presented at the 2015 American ... will include measures of sustained response in IBS-C ... placebo-controlled, randomized Phase 2 trial. The meeting will ...
(Date:10/8/2015)... 2015  Trovagene, Inc., (NASDAQ:   TROV) a ... presentation of results from a field experience analysis ... SM (PCM) platform to accurately identify mutational ... determine appropriate therapy for patients. Mark Erlander ... delivering the results today in an oral presentation ...
(Date:10/8/2015)... 2015  Following months of investigation, Ross Feller Casey ... alleging that the anticoagulant Xarelto,s recommended dosage doesn,t work for ... Philadelphia on behalf of a ... the drug didn,t work as the manufacturer suggested. Ross ... shortly on behalf of clients from across the country with ...
Breaking Medicine Technology:
... CLARA, Calif., Oct. 7, 2011 ProteinSimple today ... and field service support for its biologics products ... product lines are included in this expanded support ... Micro-Flow Imaging systems. The biologics market ...
... (Nasdaq: CPHD ) today announced that it will ... 30, 2011, on Thursday, October 20, 2011, after the close ... management presentation at 2 p.m. Pacific Time on Thursday, October ... webcast, please visit Cepheid,s website at at ...
Cached Medicine Technology:
(Date:10/10/2015)... ... ... The sixth annual cost of cybercrime study the Ponemon Institute released this ... The New York Times broke down some of those numbers in this article ... the companies surveyed, it only proves that regular threat assessments, penetration testing and emergency ...
(Date:10/10/2015)... ... ... Story Chaser is a one-of-a-kind app that makes reading fun while helping children ... words drop down and users tap the corresponding word. By answering correctly player earn ... making it a more engaging game. Users can use what are called Reading Powers ...
(Date:10/10/2015)... Arbor, MI (PRWEB) , ... October 10, 2015 , ... ... City, MO. , On the heels of the release of the Institute of ... of tools, and their integration with Cerner solutions that assist healthcare providers and consumers ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, ... Place To Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The ... up with a celebratory gala on October 1st. , Many of the features ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... the Pacific Associate Dean for Graduate Medical Education J. Michael Finley, DO, as ... Award. Finley was selected for his impact on graduate medical education opportunities for ...
Breaking Medicine News(10 mins):
... CardioCareLive, the world,s largest live online cardiology congress ... Medicine, today announced three new complimentary Continuing Medical ... days on Tuesday June 28th and Wednesday June ... and internal medicine and family care physicians in ...
... latest episode in the American Chemical Society,s (ACS) ... focuses on new blood test that can quickly ... bacterium that,s become a global threat, significantly improving ... Staphylococcus aureus, or simply MRSA. The podcast explains ...
... 24 (HealthDay News) -- Rain-making bacteria may shed some ... the Earth,s precipitation cycle, new research shows. ... meeting of the American Society for Microbiology in New ... of hailstones, suggesting that airborne microorganisms may trigger precipitation, ...
... knowledge of tuberculosisas well as in the practices, programs ... with human immunodeficiency virus (HIV)the spread of multidrug-resistant (MDR) ... community. Research in the June issue of The ... use of 18F-FDG positron emission tomography (PET) scans can ...
... MA Electronic medical records (EMRs) have been in use ... utilization in recent years, due in part to research supporting ... become a standard in medical care, there is a need ... be refined. A group of researchers from Brigham and Women,s ...
... you may want to think twice before shooting hundreds of ... study from MIT neuroscientists shows that the most memorable photos ... and human-scale objects. Landscapes? They may be beautiful, but they ... are not the same," says MIT graduate student Phillip Isola, ...
Cached Medicine News:
The MACS VA_500 (variable atmosphere) is primarily for the study and isolation of microaerophilic organisms,including Campylobacter spp,Helicobacter pylori and other similarly fastdious organisms....
... an electrical power supply, MERKUR offers a broad ... a gas spring for ease of operation. For ... a foot pedal hydraulic system. Thanks to its ... anytime in a highly mobile and flexible manner. ...
... The operating table MARS Enduro ... examinations or interventions are required before, ... Due to the motorised longitudinal adjustment ... provides optimum working conditions in examination, ...
... Exclusive, 210° Top Rotation provides uncommon ... surgery. The Hercules 6700B eliminates any ... head-end procedures, while providing ample leg ... sit during procedures. Removable back and ...
Medicine Products: